NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Lockheed Martin Corporation ("Lockheed Martin" or the "Company") (NYSE: LMT) between January 23, 2024 and July 21, 2025, inclusive. Should You Join This Class Action Lawsuit? If you purchased or acquired Lockheed Martin securities, and/or would like to discuss your legal rights and options ...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired publicly traded Sable Offshore Corp. ("Sable Offshore" or the "Company") (NYSE: SOC) securities between May 19, 2025 and June 3, 2025, inclusive (the "Class Period"), and/or pursuant and/or traceable to the Company's May 21, 2025 secondary public offering. Should You Join This Class Action Lawsuit? If you pu ...

Group 1 - A shareholder has filed a securities class action lawsuit against Replimune Group, Inc. and certain senior officers, alleging violations of the Securities Exchange Act of 1934 for the period between November 22, 2024, and July 21, 2025 [1] - The lawsuit claims that the defendants made misrepresentations regarding the IGNYTE trial's prospects for RP1, a cancer drug, in combination with nivolumab for treating advanced melanoma [3] Group 2 - Replimune's lead drug product candidate is RP1, which is focused on cancer treatment [3] - The law firm Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against RxSight, Inc. for allegedly overstating product demand and failing to disclose sales declines due to adoption challenges and structural issues [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired RxSight securities between November 7, 2024, and July 8, 2025 [1]. - Defendants are accused of misrepresenting the demand for RxSight's products and not revealing significant challenges affecting sales [3]. Legal Process - Investors wishing to serve as lead plaintiffs must file necessary documents by September 22, 2025 [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S on behalf of investors who purchased or acquired the company's securities between May 7, 2025, and July 28, 2025, alleging misrepresentations regarding the company's growth potential related to its diabetes/obesity drug, GLP-1 [1][2]. Group 1 - The lawsuit claims that the defendants made misrepresentations concerning Novo's growth potential stemming from the Company's diabetes/obesity drug, GLP-1 [2]. - Investors who purchased Novo securities during the specified period are encouraged to discuss their legal rights and options [2]. - A lead plaintiff must file papers by September 30, 2025, to represent the class in the litigation [3]. Group 2 - Bernstein Liebhard LLP has recovered over $3.5 billion for its clients since 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired common stock of Lineage, Inc. in connection with the Company's July 2024 IPO [1][2] - The lawsuit alleges that the defendants made misrepresentations regarding Lineage's business, historical financial results, and industry trends at the time of the IPO [2] Summary by Sections - **Lawsuit Details** - The lawsuit is aimed at investors who bought shares during the IPO and claims misrepresentation by the defendants [1][2] - Investors wishing to serve as lead plaintiff must file by September 30, 2025, and representation is on a contingency fee basis [3] - **Firm Background** - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S, alleging misrepresentations regarding the company's growth potential related to its diabetes/obesity drug, GLP-1, during the period from May 7, 2025, to July 28, 2025 [1][2]. Group 1 - The lawsuit is on behalf of investors who purchased or acquired Novo Nordisk's securities within the specified timeframe [1]. - Defendants are accused of making false statements about the company's growth prospects linked to its GLP-1 drug [2]. - Investors wishing to serve as lead plaintiffs must file by September 30, 2025, and participation does not require serving as lead plaintiff [3]. Group 2 - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Sable Offshore Corp. (“Sable Offshore” or the “Company”) (NYSE: SOC) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Sable Offshore Corp. (NYSE: SOC)? Did you purchase your shares between May 19, 2025 and June 3, 2025, inclusive, and/or pursua ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Lockheed Martin Corporation, alleging violations of the Securities Exchange Act of 1934 due to misrepresentations regarding the company's internal controls and risk-adjusted profit booking rate [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated on behalf of investors who purchased Lockheed Martin securities between January 23, 2024, and July 21, 2025 [3]. - Defendants in the lawsuit include the company and certain senior officers, accused of making false statements about the company's internal controls [4]. Group 2: Legal Process and Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by September 26, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [6].

All representation is on a contingency fee basis. Shareholders pay no fees or expenses. NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Fiserv, Inc. ("Fiserv" or the "Company") (NYSE: FI) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? If you purchased or acquired Fiserv common stock, and/or would like to discuss your legal ...